欧洲及中国在医药、生物领域不可专利客体方面的比较  

Comparison Between the EPO and the CNIPA with Respect to Non-Patentable Subject-Matter in the Pharmaceutical/Biotechnological Field

作　　者：谢敏楠 Astrid YOUNG XIE Minnan;Astrid YOUNG(Beijing Wan Hui Da Law Firm (Guangzhou office), Guangzhou 510610;European Patent Office, Munich 82041)

机构地区：[1]北京市万慧达(广州)律师事务所,广州510610 [2]欧洲专利局,慕尼黑82041 [3]广东省知识产权局知识产权专家库

出　　处：《中国发明与专利》2019年第6期92-99,共8页China Invention & Patent

摘　　要：《欧洲专利公约》及《中华人民共和国专利法》均对不可专利客体进行了规定。对于医药、生物领域的发明创造,欧洲专利局(EPO)与中国国家知识产权局(CNIPA)的实践各有不同。了解EPO和CNIPA各自的实践和标准,有利于申请人在欧洲、中国进行恰当而深度的专利申请与保护。Both the European Patent Convention and the Patent Law of the People's Republic of China have stipulated exceptions to patentability. In the field of pharmaceutical and biotechnological inventions, differences exist between the practice in the European Patent Office (EPO) and the China National Intellectual Property Administration (CNIPA). An understanding of the practice and the standards in the EPO and the CNIPA, can help applicants to gain suitable and in-depth patent portfolio and protection in these areas.

关 键 词：欧洲专利公约 中国专利法 不可专利客体 

分 类 号：D923.42[政治法律—民商法学]